Satish K Surabhi . MD.FACC.FSCAI.RPVI Medical Director ... ¢â‚¬› portals...

download Satish K Surabhi . MD.FACC.FSCAI.RPVI Medical Director ... ¢â‚¬› portals ¢â‚¬› 16 ¢â‚¬› surabhi-pcsk9-cvs16.pdf¢ 

of 34

  • date post

    24-Jun-2020
  • Category

    Documents

  • view

    0
  • download

    0

Embed Size (px)

Transcript of Satish K Surabhi . MD.FACC.FSCAI.RPVI Medical Director ... ¢â‚¬› portals...

  • Satish K Surabhi. MD.FACC.FSCAI.RPVI Medical Director, Cardiac Cath Labs

    AnMed Heart & Vascular Care

  •  None

  •  Evolocumab ( 2976) vs Standard Rx (1489)  All CV events 0.95% vs 2.18%  MACE 0.95% vs 2.1 %  Death 0.14% vs 0.41%

     Curves separated early

  •  Cost  Access to medicines  Compliance  Neurocognitive effects 0.9 % vs 0.3%  Long term follow up studies

  •  Outcome studies in various populations

     Longer acting agents.. Q 6 months? Q 1yr?

     Vaccine ?

     Combined/ sequential/ intermittent therapy

    PCSK9 Inhibitors Financial conflict of interest Statins- standard of CV Care Unmet needs in Lipid Rx for CVD Slide Number 5 Slide Number 6 Slide Number 7 What is PCSK9 ? PCSK9 Gain of function Slide Number 10 Slide Number 11 Slide Number 12 Slide Number 13 Slide Number 14 Slide Number 15 Slide Number 16 Slide Number 17 Slide Number 18 Slide Number 19 Slide Number 20 Slide Number 21 Slide Number 22 Dramatic LDL Reductions Excellent reductions of Lp(a) Effect of PCSK9 Monoclonal Antibodies on ApoB and Lp(a) GAUSS-1�% Change in LDL-C From Baseline at Week 12 in Statin-Intolerant Patients How Low Is Too Low? PCSK9 CV Outcomes Trials Slide Number 29 Slide Number 30 Slide Number 31 Osler 1 and Osler 2�(personal communication) Concerns Future Directions